Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Sees Large Increase in Short Interest

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 27,721 shares, a growth of 169.9% from the June 30th total of 10,271 shares. Based on an average daily trading volume, of 10 shares, the short-interest ratio is presently 2,772.1 days.

Laboratorios Farmaceuticos Rovi Stock Performance

OTCMKTS:LABFF remained flat at C$64.77 on Monday. The stock’s fifty day moving average is C$65.69 and its 200-day moving average is C$65.80. Laboratorios Farmaceuticos Rovi has a one year low of C$65.86 and a one year high of C$65.86.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.